Acquisition
Jul 2025Persephoni BioPartners said it launched Telos Therapeutics via a strategic acquisition of key assets, data packages, and early-stage programs from Entelexo Biotherapeutics.
SourceCreating a New Class of Drugs to Address Incurable Autoimmune Diseases
Company research
Public company, workplace, funding, and market signals
Overview
Entelexo Biotherapeutics is an Irvine-based biotech developing engineered exosome therapeutics for complex autoimmune diseases using a proprietary platform that targets multiple cell types and aims to move beyond single-cytokine treatments.
Primary product
Engineered exosome-based therapeutics for autoimmune disease
Founded
2020
Headquarters
Irvine, California, United States
Team size
1-10
Industry
Pharmaceutical Manufacturing
Sub-industry
Exosome therapeutics / drug discovery
Offices
5270 California Ave, Ste 300, Irvine, CA 92617-3231
Irvine, California, United States
Business model
preclinical drug development
platform therapeutics
potential licensing and partnering
Funding
Stage
Seed / pre-clinical
Total raised
$2.6M
Latest round
Early Stage VC · May 2023
Latest amount
$50K
People & investors
Leadership
Co-Founder and CEO
Co-Founder and COO
Co-Founder and CTO
Work & culture
Small, mission-driven, research-heavy biotech with a lab-centric, preclinical development focus.
Compensation
No public compensation or salary data found; no jobs were posted on YC at the time of review.
Product & market
Pricing
Not publicly disclosed; preclinical biotech development with potential future partnering/licensing
Differentiators
- —Engineered exosomes designed to communicate with multiple specific cell types simultaneously
- —Focus on complex autoimmune diseases such as psoriasis, Crohn's disease, and rheumatoid arthritis
- —Human cell assay de-risking before IND-enabling studies
- —Rational engineering platform for rapid indication-specific prototyping
- —Patent-protected pipeline
Technology
engineered exosomes
proprietary exosome engineering platform
human cell immunoassays
preclinical animal studies
IND-enabling studies
patent portfolio
data-driven optimization
Competitors
Biogen
BeiGene
AbCellera Biologics
Sana Biotechnology
argenx
DBV Technologies
Scale & contact
Signals & risks
Latest news
Persephoni Bio / LinkedIn · Jul 2025
Public post says Telos Therapeutics launched from a strategic acquisition of key assets, data packages, and early-stage programs from Entelexo Biotherapeutics.
PRNewswire · Nov 2023
ULP won a $2M Build to Scale award and highlighted resident company Entelexo, including co-founder/CTO Cameron Taylor and the company's exosome-engineering work.
University Lab Partners / YouTube · Oct 2022
Video interview with the CTO explaining the exosome engineering platform and the clinical background behind the company's approach.
KingsCrowd · Jun 2021
Crowdfunding analysis describing Entelexo's valuation cap, use of proceeds, and prior funding trajectory at the time of the Wefunder raise.
Jobs and careers at Entelexo Biotherapeutics
0 jobs at Entelexo Biotherapeutics
No open positions
Check back later for new openings